field brief · no. 003 · dose card
Dose Card
routes, ladders, ceilings
01
Smoked · dried petal
fast onset · short duration| vehicle | loose dried petal in a small pipe or joint |
|---|---|
| onset | 30–90 seconds (first inhale) |
| peak | 5–10 min after first puff |
| duration | 20–45 min total |
| combines with | mugwort (dream) · damiana (mild relax) · mullein (smoothness) |
| tier | weight | expected | side effects |
|---|---|---|---|
| threshold | 0.1–0.25 g | faint warmth, mild relaxation | rare; may not register |
| mild | 0.25–0.5 g | calm focus, light body sensation | mild dry mouth |
| regular | 0.5–1 g | strong relaxation, mild closed-eye visuals | mild dizziness if standing fast |
| strong | 1–1.5 g | heavy body, dream-like on closing eyes | nausea if combined with alcohol |
| ceiling | > 1.5 g | not recreational — side effects dominate | headache, nausea, dizziness |
02
Vaped · concentrate / e-liquid
highest extraction · respect ceiling| vehicle | 510 cart · RBA dripping atomizer · concentrate on quartz |
|---|---|
| onset | 10–30 seconds (first draw) |
| peak | 3–8 min after first draw |
| duration | 15–30 min total |
| caveat | vape delivers 3–5× more alkaloid per gram than smoking |
| tier | weight / draw count | expected | side effects |
|---|---|---|---|
| threshold | 1 small draw (2–3 sec) | faint taste, light head | dry throat |
| mild | 2–3 small draws | calm, focus, mild closed-eye warmth | dry mouth |
| regular | 4–6 draws over 10 min | deep relaxation, dream imagery | possible lightheadedness |
| strong | 7–10 draws | heavy body, strong visuals with eyes closed | headache, dry mouth |
| ceiling | > 10 draws or > 0.5 g/day | side effects dominate · headache + nausea common | nausea, dizziness, racing thoughts |
03
Tea or wine infusion
slow onset · longest duration| vehicle | 1 g petal per 250 ml water · 15 min steep · red wine maceration 1–3 days |
|---|---|
| onset | 10–25 min (oral) |
| peak | 45–75 min after dose |
| duration | 2–3 h total |
| with food | onset delayed 15–30 min · mild effect |
| alcohol pairing | amplifies sedative + nauseant risk · dose to ~50% of sober |
| tier | dried petal weight | expected | side effects |
|---|---|---|---|
| threshold | 1 g | warmth, light relaxation | rare |
| mild | 3 g | calm, gentle mood lift | mild drowsiness |
| regular | 5 g | strong relaxation, dream-like on close | sleepiness, dry mouth |
| strong | 10 g | very relaxed, vivid dreams, sleep | morning grogginess |
| ceiling | > 10 g | side effects dominate | headache, nausea, GI upset |
04
Tincture · alcohol extract
standardizable · slow onset| vehicle | 1:5 40% alcohol extract · 4–6 week maceration |
|---|---|
| onset | 15–30 min (sublingual) · 25–45 min (oral) |
| peak | 60–90 min after dose |
| duration | 2–4 h total |
| caveat | concentration varies; standardized extracts emerging |
| tier | dose | expected | side effects |
|---|---|---|---|
| threshold | 0.5 ml | faint relaxation | rare |
| mild | 1–1.5 ml | calm, mild warmth | mild drowsiness |
| regular | 2–3 ml | relaxation, dream enhancement | sleepiness |
| strong | 4–5 ml | deep relaxation, sleep | grogginess |
| ceiling | > 5 ml | side effects dominate | headache, GI upset |
05
Absolute don'ts
combinatorial · demographic · context- Don't combine with MAOIs (harmala alkaloids / passionflower / moclobemide / SSRIs combined with MAOIs). Theoretical serotonin-syndrome risk from the aporphine + β-carboline overlap.
- Don't combine with antipsychotics. The D1/D2 antagonist profile is mechanistic overlap; blue lotus likely attenuates effect.
- Don't combine with sedatives (benzodiazepines, barbiturates, alcohol at high dose, opiates). Sedative stacking compounds strongly.
- Don't drive or operate machinery within 4 hours of any dose above mild.
- Not for pregnancy / nursing. No human safety data; aporphine alkaloids cross placental barriers in animal models.
- Not for people with cardiovascular conditions (arrhythmia, low BP, on blood-pressure meds). Apomorphine causes hypotension.
- Not for Parkinson's patients (on apomorphine therapy). Apomorphine overlap can dysregulate dosing.
- Under-25 neurodevelopment is the highest uncertainty window. No human trial data; the dopaminergic system is still maturing.
06
Sources & methodology
where the dose ranges come fromDoses on this card are not derived from controlled clinical trials. Blue lotus has no published dose-ranging human studies. The numbers are aggregated from:
- The Blue Lotus Flower (Nymphea caerulea) Resin Used in a New Type of Electronic Cigarette, the Re-Buildable Dripping Atomizer. PMC 5638439 — vape-route pharmacokinetic estimate.
- Chemical Composition, Market Survey, and Safety Assessment of Blue Lotus (Nymphaea caerulea Savigny) Extracts. PMC 10609367 (2023) — alkaloid concentration ranges across commercial products.
- Vendor guidance from Blue Bird Botanicals, Sacred Blue Lotus, Herbalistics — practical dose reports.
- Erowid experience reports (cross-checked against the above).
- Superpower. Blue Lotus Tea: What It Does to Your Brain and Whether It's Legal. Updated May 2026.
- Operation Supplement Safety (DoD). Blue lotus: prohibited for use. Updated April 2024.
Side-effect categories (headache, nausea, dizziness, dry mouth, drowsiness) are reported consistently across the above sources; incidence rates are not, because no controlled study has measured them.